benzofurans and Syndrome

Topics: Aged; Amiodarone; Benzofurans; Bradycardia; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Syndrome; Tachycardia

Prucalopride is a selective serotonin receptor agonist with prokinetic activity, indicated for women with chronic constipation in whom laxatives have failed to provide adequate relief. Data suggests an improvement in about 50 % of such patients but whether the therapeutic effect is on patients with slow transit constipation (STC) and/or obstructed defaecation syndrome (ODS), or even those with constipation-predominant irritable bowel syndrome (IBS-C) is unknown. We therefore assessed whether there is any association between prucalopride efficacy and constipation type.. All patients receiving prucalopride between June 2010 and April 2012 at our institution were identified, and data analysed following a 4-week "test" period. Patients were sub-grouped as those suffering with ODS, STC, mixed (ODS and STC) or IBS-C based on symptomatology and investigations. Subjective assessment of patient satisfaction and continuation of medication were taken as positive outcomes and analysed for each sub-type along with any side effects.. Sixty-nine patients met our criteria. Data were available for 59 women (median age 46 years, range 17-79 years). Sixty-five per cent of prescriptions came from colorectal surgeons. Overall, 25 out of 59 (42 %) patients improved, according to our criteria, after the 4-week trial period. Seventeen patients (29 %) had ODS, 26 (44 %) had STC, 7 (12 %) had mixed symptoms and 9 (15 %) had IBS-C. At 4 weeks, 10 out of 17 patients (59 %) with ODS had improved compared with 4 out of 9 patients (44 %) with IBS-C, 3 out of 7 patients (43 %) with mixed symptoms and 8 out of 26 (31 %) patients with STC. The underlying disorder did not predict whether or not a patient responded to the 4-week trial period (p = 0.32). Nine patients (15 %) experienced side effects that precluded further use.. Patients with all categories of constipation may respond to prucalopride. A trial regime may be indicated regardless of the aetiology of the constipation.

Topics: Adolescent; Adult; Aged; Benzofurans; Cohort Studies; Constipation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Transit; Humans; Intestinal Obstruction; Middle Aged; Patient Satisfaction; Retrospective Studies; Serotonin Receptor Agonists; Severity of Illness Index; Syndrome; Treatment Outcome; Young Adult

Lambert-Eaton syndrome, an autoimmune disorder frequently associated with small-cell carcinoma of the lung, is characterized by impaired evoked release of acetylcholine from the motor nerve terminal. Immunoglobulin G (IgG) antibodies from patients with the syndrome, applied to bovine adrenal chromaffin cells, reduced the voltage-dependent calcium channel currents by about 40 percent. When calcium was administered directly into the cytoplasm, however, the IgG-treated cells exhibited normal exocytotic secretion, as assayed by membrane capacitance measurement. Measurement with the fluorescent calcium indicator fura-2 indicated that the IgG treatment reduced potassium-stimulated increase in free intracellular calcium concentration. The pathogenic IgG modified neither kinetics of calcium channel activation nor elementary channel activity, suggesting that a reduction in the number of functional calcium channels underlies the IgG-induced effect. Therefore, Lambert-Eaton syndrome IgG reacts with voltage-dependent calcium channels and blocks their function, a phenomenon that can account for the presynaptic impairment characteristic of this disorder.

Topics: Adrenal Glands; Autoantibodies; Autoimmune Diseases; Benzofurans; Calcium; Carcinoma, Small Cell; Cell Membrane; Chromaffin System; Electric Conductivity; Exocytosis; Fluorescent Dyes; Fura-2; Humans; Immunoglobulin G; Ion Channels; Lung Neoplasms; Neuromuscular Diseases; Sodium; Synapses; Syndrome; Tetrodotoxin

Amiodarone is an effective antiarrhythmic that has been used in Europe for over a decade and has been available for investigational use in North America for a shorter time. It has several well recognized side effects. Recent reports have related pulmonary disorders to the use of this drug; fibrosing alveolitis has been found by lung biopsy. Amiodarone's toxicity to the lung does not appear to be dose-related. Besides cessation of amiodarone administration, management of this complication includes steroid therapy. A case is described of nonspecific diffuse alveolar damage syndrome in a patient who had received amiodarone.

Topics: Adrenal Cortex Hormones; Aged; Amiodarone; Benzofurans; Humans; Lung; Lung Diseases; Male; Pulmonary Alveoli; Radiography; Respiratory Function Tests; Syndrome

Topics: Adult; Aged; Amiodarone; Benzofurans; Bradycardia; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sinoatrial Node; Syndrome; Tachycardia

A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone.

Topics: Adolescent; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; Heart Ventricles; Humans; Male; Syncope; Syndrome

Amiodarone induces in patients "low T3-syndrome" characterized by normal T4. T3 resin uptake and free T3, contrasting with low T3 and free T4 values, and enhanced concentration of r-T3.

Topics: Amiodarone; Benzofurans; Heart Diseases; Humans; Syndrome; Triiodothyronine

Five patients with the bradycardia-tachycardia syndrome have been treated successfully with the antiarrhythmic agent amiodarone. Three patients were treated for over nine months and one of these patients had corneal micro deposits. One patient had to be taken off the drug because of side effects. Amiodarone should be tried in patients suffering from the bradycardia-tachycardia syndrome before resorting to cardiac pacing.

Topics: Aged; Amiodarone; Benzofurans; Bradycardia; Corneal Diseases; Female; Humans; Male; Middle Aged; Syndrome; Tachycardia

Topics: Angina Pectoris; Benzofurans; Furans; Syndrome; Vasodilator Agents